Saturday 17 October 2026
Export STTK’s income statement to Excel — free account
Shattuck Labs, Inc.
STTK Healthcare Biotechnology
In the quarter to June 2026, revenue fell 10.3%, EPS grew 50.0% and free cash flow grew 1.01%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.
5.42
0.11
−1.99%
Follow STTK
| Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | — | 4 | 3 | 2 | 4 | 3 | 4 |
P/E ratio |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z-Score |
— | — | — | 12.98 | 8.12 | (0.21) | 8.68 | (4.57) | 10.16 |
P/S ratio |
— | 14.36 | 14.36 | 81.81 | 11.92 | 3.45 | 194.36 | 10.74 | 45.31 |
P/FCF ratio |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
— | 3.87 | (2.54) | 13.11 | 14.14 | 4.58 | 5.51 | (7.23) | (3.77) |
P/Operating CF |
— | (13.13) | (13.13) | (57.87) | (19.11) | (4.44) | (16.58) | (3.54) | (29.92) |
P/B ratio |
— | 0.00 | 0.00 | 2.62 | 1.32 | 0.60 | 2.23 | 0.77 | 3.08 |
Price to Tangible BV |
— | 0.00 | 0.00 | 2.62 | 1.32 | 0.60 | 2.23 | 0.77 | 3.08 |
EV/Sales |
— | 1.35 | 1.35 | 48.04 | 2.96 | (1.80) | 115.53 | (2.02) | 31.38 |
EV/EBITDA |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.56 | 0.00 | 0.15 | 0.00 |
EV/Operating CF |
— | (0.52) | (0.52) | (14.18) | (1.56) | 0.59 | (2.36) | 0.19 | (4.41) |
EV/FCF |
— | (0.51) | (0.51) | (13.88) | (1.37) | 0.52 | (2.34) | 0.19 | (4.40) |
Quick Ratio |
— | 2.90 | 1.96 | 19.93 | 10.93 | 6.46 | 11.41 | 8.19 | 11.07 |
Current Ratio |
— | 3.15 | 2.12 | 20.53 | 11.72 | 7.39 | 12.51 | 8.88 | 11.70 |
Net Debt/EBITDA |
— | 10.25 | 1.58 | 9.24 | 6.58 | 1.63 | 1.46 | 0.93 | 1.62 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
— | 0.66 | 0.17 | 0.05 | 0.09 | 0.00 | 0.01 | 0.05 | 0.01 |
Operating CF/Net income |
— | 0.93 | 0.87 | 0.92 | 1.27 | 0.93 | 0.93 | 0.80 | 0.82 |
Capex/Depreciation |
— | 0.00 | (1.27) | (1.17) | (1.80) | (2.59) | (0.16) | (0.04) | (0.02) |
Interest Coverage |
— | (3.42) | — | — | — | — | — | — | — |
| — | 32.38% | 105.12% | (26.59%) | (15.46%) | (45.52%) | (54.41%) | (67.23%) | (60.25%) | |
| — | (21.68%) | (42.40%) | (18.58%) | (13.89%) | (40.46%) | (47.85%) | (60.18%) | (53.61%) | |
ROIC |
— | 0.00% | 0.00% | 0.00% | (948.80%) | (434.10%) | (408.19%) | (758.46%) | (744.34%) |
Return on Tangible Assets |
— | (15.62%) | (96.33%) | (11.03%) | (16.44%) | (57.50%) | (59.97%) | (94.13%) | (59.86%) |
Average Days of Receivables |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Research and Development Expense of Revenue |
— | 110.54% | 295.52% | 377.32% | 188.44% | 12,714.57% | 4,484.61% | 1,174.81% | 3,527.30% |
Selling, General and Administrative Expense of Revenue |
— | 15.72% | 58.02% | 94.44% | 62.37% | 3,233.44% | 1,165.00% | 333.46% | 1,723.50% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
— | 0.00% | 4.66% | 12.74% | 18.21% | 991.10% | 418.77% | 166.86% | 699.50% |
Graham Net Nets |
— | 0.71 | 0.71 | 0.38 | 0.73 | 1.47 | 0.40 | 1.10 | 0.29 |
Graham Number |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
— | (21.57%) | (21.57%) | (6.72%) | (12.46%) | (96.40%) | (27.12%) | (123.14%) | (21.10%) |
Free Cash Flow Yield |
— | (18.65%) | (18.65%) | (4.23%) | (18.18%) | (100.06%) | (25.35%) | (98.65%) | (15.75%) |
Revenue per Share |
— | 0.54 | 1.31 | 0.64 | 0.71 | 0.02 | 0.04 | 0.11 | 0.01 |
Operating CF per Share |
— | (0.17) | (2.78) | (2.17) | (1.36) | (2.23) | (1.91) | (1.19) | (0.57) |
Capex per Share |
— | 0.00 | (0.06) | (0.05) | (0.19) | (0.27) | (0.01) | 0.00 | 0.00 |
Free Cash Flow per Share |
— | (0.17) | (2.84) | (2.22) | (1.55) | (2.50) | (1.92) | (1.19) | (0.57) |
Cash per Share |
— | 1.45 | 5.17 | 21.63 | 6.40 | 3.81 | 3.07 | 1.44 | 1.12 |
Shareholders Equity per Share |
— | 0.91 | 1.92 | 19.98 | 6.47 | 4.16 | 3.40 | 1.57 | 1.18 |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
— | 0.91 | 1.92 | 19.98 | 6.47 | 4.16 | 3.40 | 1.57 | 1.18 |
Free Cash Flow |
— | (6.90) | (21.44) | (34.39) | (65.04) | (106.01) | (81.63) | (60.57) | (39.95) |
Working Capital |
— | 44.78 | 22.46 | 328.81 | 263.68 | 159.62 | 131.77 | 70.30 | 75.42 |
Capital Expenditures |
— | (1.18) | (0.47) | (0.73) | (7.93) | (11.51) | (0.41) | (0.06) | (0.07) |
Net Current Asset Value |
— | 35.46 | 11.99 | 306.51 | 261.47 | 155.42 | 128.36 | 67.79 | 73.84 |
EV/EBIT |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.54 | 0.00 | 0.14 | 0.00 |
Capex to Sales |
— | 0.00 | 0.05 | 0.07 | 0.26 | 17.65 | 0.25 | 0.01 | 0.07 |
Price to Operating Income |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | |||||||||
Depreciation/Fixed assets |
— | 0.10 | 0.15 | 0.21 | 0.44 | 0.25 | 0.19 | 0.17 | 0.53 |
Cash ROIC |
— | (7.02%) | (40.01%) | (5.33%) | (12.03%) | (31.42%) | (29.65%) | (39.69%) | (24.90%) |
Accounts Receivable Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Accounts Payable Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | — | — | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | — | — | 0.00 | 0.00 | — | — | — |
Average Payables |
— | 2.55 | 2.55 | 2.40 | 5.88 | 8.59 | 4.38 | 2.00 | 2.26 |
Average Assets |
— | 34.08 | 56.57 | 196.98 | 323.79 | 251.95 | 182.44 | 125.31 | 91.04 |
Average Common Equity |
— | (22.81) | (22.81) | 137.66 | 290.82 | 223.97 | 160.43 | 112.17 | 81.01 |
Columns are period end dates